S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$20.03
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

OPNT stock logo

About Opiant Pharmaceuticals (NASDAQ:OPNT) Stock

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Dechra Pharmaceuticals defies cooling pets market
Indivior To Buy Opiant For $145 Mln In Cash
Indivior PLC to Acquire Opiant Pharmaceuticals
See More Headlines

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Company Calendar

Last Earnings
11/11/2021
Today
5/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Profitability

Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Book Value
$9.92 per share

Miscellaneous

Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links


Key Executives

  • Roger CrystalRoger Crystal
    President, Chief Executive Officer & Director
  • David D. O'TooleDavid D. O'Toole
    Chief Financial Officer & Secretary
  • Phil SkolnickPhil Skolnick
    Chief Scientific Officer
  • Mark Jason H. Ellison
    Chief Development Officer
  • Matthew R. RuthMatthew R. Ruth
    Chief Commercial Officer













OPNT Stock - Frequently Asked Questions

Should I buy or sell Opiant Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OPNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPNT, but not buy additional shares or sell existing shares.
View OPNT analyst ratings
or view top-rated stocks.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) issued its quarterly earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.41. The technology company had revenue of $16.34 million for the quarter, compared to analysts' expectations of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%. During the same quarter in the previous year, the business earned $0.15 EPS.

What other stocks do shareholders of Opiant Pharmaceuticals own?
What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How much money does Opiant Pharmaceuticals make?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a market capitalization of $0.00 and generates $47.78 million in revenue each year. The technology company earns $3.01 million in net income (profit) each year or ($6.56) on an earnings per share basis.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The official website for the company is www.opiant.com. The technology company can be reached via phone at (310) 598-5410, via email at investor.relations@opiant.com, or via fax at 917-322-2105.

This page (NASDAQ:OPNT) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -